Articles tagged with Metastasis
A new study finds that high-dose radiation therapy can lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted tumor growth or spread. Stereotactic body radiation therapy (SBRT) shows promise in treating oligoprogressive, metastatic lung and breast cancer.
A new, bacteria-based system can detect cancer cells and release therapeutic drugs directly into them, leaving healthy cells intact. The technology has shown promising results in preclinical tests on mice, particularly for liver cancer.
Researchers from UPV/EHU and Biocruces pathologists use game theory to study tumor cell interactions, finding that higher cell diversity may be beneficial for patients. This approach reveals the importance of collective stability in tumor cells' pursuit of better environments.
Researchers found that aggressive triple-negative breast cancer cells use swiprosin-1 to hijack a cellular conveyor belt, increasing integrin circulation and cell migration. High swiprosin-1 expression correlates with metastasis formation and malignancy in breast cancer.
Researchers at Sunnybrook Health Sciences Centre have successfully delivered antibody therapy to breast cancer metastases in the brain using focused ultrasound. The treatment, which temporarily opens the blood-brain barrier, has shown promising results with tumor size reductions of up to 21% in patients.
New research reveals that boosting numbers of immune cells called dendritic cells may be key to overcoming colorectal cancers' immunotherapy resistance. By augmenting dendritic cells in liver metastases, treatment led to increased cytotoxic T lymphocytes and made tumors sensitive to immune checkpoint inhibitors.
Researchers have discovered the molecular mechanisms behind stem cell rolling in blood vessels, a complex process that slows down cells using long tethers. The findings offer new insights into improving stem cell transplantations and developing treatments for metastasizing cancers.
A new study reveals a small molecule, RGX-202, that targets and prevents metastasis in colorectal cancer by blocking the uptake of phosphocreatine into cancer cells. The findings have led to a clinical trial in humans and may eventually increase survival rates for multiple gastrointestinal cancers.
A research team at TUM has discovered that the protein TIMP1 is associated with a significantly higher risk of liver metastasis and death in male patients, particularly those with pancreatic, colon, and melanoma cancers. This finding may lead to improved diagnosis and targeted therapy options for men.
Researchers discovered a combination of two drugs can reduce inflammation following chemotherapy, preventing metastasis in pancreatic and liver cancer. The treatment targets the sEH and EP4 pathways, modulating inflammation to resolve cytokine storms.
Researchers discovered that adrenal gland metastases are unresponsive to checkpoint inhibitors due to the secretion of corticosteroids. Surgical removal is the current best course of action for patients with these metastases. The study's authors hope to develop a nonsurgical treatment option in the future.
Researchers identified two subtypes of metastatic prostate cancer that respond differently to hormone treatment. Luminal tumors responded better to testosterone-blocking treatments, while basal tumors did not benefit as much from this hormone treatment.
Researchers analyzed data from over 3,200 brain metastatic tumors and discovered that different types of cancer tend to spread to specific parts of the brain. The study's findings may help predict where a particular cancer will metastasize and inform treatment strategies.
Researchers from FAU and MIT develop a microfluidic assay to study the mechanical performance of red blood cells under hypoxic conditions. The study reveals that cyclic hypoxia can lead to mechanical degradation of the red blood cell membrane, contributing to aging.
Scientists discovered a protein, IL13Ra2, that promotes brain metastases in breast cancer patients. High levels of this protein are associated with poor survival rates. Researchers aim to develop targeted therapies for this specific population.
Two phase III trials by VHIO researchers reveal significant clinical activity of trastuzumab deruxtecan in HER2-positive metastatic breast cancer, with over half of patients experiencing two years without disease progression. Trastuzumab duocarmazine also shows promise in treating HER2-negative breast cancer and other tumor types.
The MONALEESA-2 trial found that adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with HR-positive, HER2-negative advanced breast cancer. The combination of endocrine therapy and the CDK 4/6 inhibitor ribociclib also extends progression-free survival.
The KEYNOTE-826 study found that adding immunotherapy to standard first-line treatment increases overall survival by eight months for patients with recurrent, persistent or metastatic cervical cancer. The addition of pembrolizumab to chemotherapy also reduced the risk of death and disease progression by 33%.
A novel population of long-lived T cells, called 'lymph node resident memory T cells,' provides protection against melanoma by persisting in lymph nodes. These cells were found to counteract melanoma spreading in mice and predicted better outcomes for human melanoma patients with lymph node metastases.
Researchers developed a treatment using cowpea mosaic virus nanoparticles that target lung tumors, slowing tumor growth and preventing cancer spread. The treatment showed efficacy against aggressive cancer cell lines and may offer protection to patients at high risk of metastatic disease.
The Phase III POSEIDON trial demonstrated a statistically significant improvement in progression-free survival and overall survival for patients with metastatic non-small cell lung cancer (mNSCLC) treated with chemotherapy plus durvalumab and tremelimumab. Durvalumab combined with tremelimumab and chemotherapy reduced the risk of death...
The Vilcek Foundation has awarded four prizes worth $250,000 to foreign-born scientists in the United States. The prizes recognize outstanding career contributions to biomedical science and innovative research. This year's recipients include Vishva M. Dixit, Markita del Carpio Landry, Hani Goodarzi, and Harris Wang.
Research from Osaka City University reveals that hepatocellular carcinoma survival decreases as poorly differentiated tumor size increases. Tumors over 5cm have a significantly higher risk of early recurrence and spreading to other parts of the body.
Researchers identified a new growth factor produced by blood vessels that enables tumor cells to metastasize. The study, led by Hellmut Augustin, found that the production of LRG1 promotes the formation of a microenvironment that stimulates cancer cell growth and colonization.
A study in HNSC patients found that specific microRNAs, such as hsa-miR-203a-3p, mir-10a-5p, and miR-194-5p, are strongly associated with lymphovascular invasion (LVI). These miRNAs regulate biological pathways involved in tumor progression, making them potential prognostic indicators.
A new combination treatment has shown significant tumor shrinkage and prolonged survival in patients with metastatic uveal melanoma. The treatment, which targets HDAC and PD-1 proteins, was found to work better in tumors with active BAP1 genes, a key discovery that may lead to improved survival rates.
Researchers at Duke University Medical Center identified a mechanism where breast cancer cells use cholesterol to develop tolerance to stress, allowing them to resist ferroptosis and proliferate. This finding highlights the importance of lowering cholesterol in preventing cancer progression and offers new approaches for treatment.
Patients with relapsed metastatic melanoma who received prior anti-PD-1 therapies had a lower response rate to adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL). ACT-TIL was less effective in these patients compared to those who had never received anti-PD-1 therapy. The study found that the objective response rate and ...
A recent study by Chinese Academy of Sciences researchers found that circular RNA circURI1 inhibits the spread of gastric cancer cells. It achieves this by sequestering hnRNPM, modulating alternative splicing in gastric cancer cells. This breakthrough provides a new perspective on the molecular basis of cancer metastasis.
Researchers have found that breast cancer stem cells accumulate near a tumor arteriole, which they call the arteriolar niche. This niche promotes cancer cell features and potential development through the LPA/PKD-1 signaling pathway.
Researchers at Massachusetts General Hospital have identified two separate genetic alterations that enable triple-negative breast cancer cells to develop resistance to a highly effective drug. The findings could help improve therapy and prolong survival for patients with this aggressive form of breast cancer.
Researchers discovered that hypoxia induces regional variations in gene-expression patterns in pancreatic cancer, with specific subpopulations of cancer cells surviving under hypoxic conditions. These findings suggest a link between hypoxia and aggressive tumor behavior, highlighting the need for targeted treatments.
Researchers at City of Hope found that advanced colorectal cancer patients with no liver metastases respond to checkpoint inhibitors, achieving a major response in 20% of cases. In contrast, patients with liver metastases showed no positive response to immunotherapy.
Prokineticin-1 is a lymphangiogenic factor involved in human colorectal cancer's lymph node metastasis and lymph vessel formation. High PROK1 expression was found to significantly increase the rate of lymph node metastasis.
Researchers found that microscopic defects in healthy cell alignment can slow down tumor cell invasion. The study used an experimental model to show how topological defects affect the rate of tumor cell invasion, with certain defects causing cancer cells to pass through the barrier more slowly.
Researchers have found a way to harness the power of immunotherapy for advanced prostate cancer by targeting a protein called PIKfyve. Blocking PIKfyve with the inhibitor ESK981 has been shown to increase tumor death and recruit immune T cells, offering new hope for patients with this challenging form of cancer.
Researchers found that cancer cells in lymph nodes avoid immune destruction due to increased physical forces causing impairment of T cell entry. Alleviating solid stress with losartan boosts blood vessels and T cells, suggesting a potential strategy to improve immune responses.
A study found that 50% of metastatic colorectal cancer patients treated with bevacizumab experienced RAS mutation disappearance, suggesting the drug's potential to revert tumors. This discovery may open new therapeutic avenues for primarily RAS mutant patients.
A preclinical study identifies a small molecule inhibitor, KCN1, that dampens tumor drivers and limits disease progression. The study showed KCN1 to be well-tolerated and effective at reducing metastasis, suggesting potential as a treatment for metastatic uveal melanoma.
A new study published in PNAS has identified a protein called AXL as a crucial player in hypoxia, which promotes cancer progression and resistance to treatment. By blocking the action of this protein, researchers observed improved recovery of blood vessels and revitalization of the tumour's immune environment.
Researchers found that reducing PTHrP levels can prevent metastasis and improve survival in mice with pancreatic cancer. The study also showed promising results with anti-PTHrP antibodies targeting human pancreatic cancer cells, offering a new potential treatment approach.
The German National Academy of Sciences Leopoldina hosted a virtual symposium to discuss cancer research, particularly pancreatic cancer, and palliative care. Experts shared insights into the development of rare pancreatic tumors, mechanisms leading to metastasis formation, and resilience in palliative care.
Researchers at University of Arizona Health Sciences found that cancer cells become more aggressive when exposed to tissue stiffening, leading to changes that persist over time. The 'mechanical conditioning' score can quantify these cellular changes and predict patients at high risk for bone metastasis.
Research led by USC investigators reveals that the ABAT enzyme helps medulloblastoma cells feed on GABA in cerebrospinal fluid, allowing them to survive and resist treatment. The study also shows that high levels of ABAT enable medulloblastoma metastases to evade treatment and spread to other parts of the central nervous system.
Researchers identified FTO as a key regulator of cancer metastasis and found that lowering its levels enhances WNT signaling, making tumors more sensitive to WNT inhibitors. This discovery offers encouraging prospects for treating aggressive cancers.
A study published in Journal of Thoracic Oncology found that low-dose computed tomography (LDCT) screening for primary lung cancer is associated with a lower risk of developing brain metastases. Researchers identified 1502 participants diagnosed with lung cancer between 2002 and 2009, where LDCT screening was detected versus other meth...
A new classification of metastatic testicular cancer enables more targeted treatment, improving survival rates. The study reveals significant improvements in prognosis for patients with testicular cancer, with increased 5-year survival rates across all groups.
A team of scientists has developed a new method for tracing the lineage and gene expression patterns of metastatic cancer cells at the single-cell level. The researchers found that a spectrum of aggression exists in cancer cells, with some cells more likely to remain in place and others more likely to spread to other tissues.
Researchers analyzed 36 patients with skin squamous-cell carcinoma, finding that CD8+ T cells infiltrated tumors with lymphatic endothelial cells. Perineural infiltrated sSCC without metastasis showed low lymphatic endothelial cell density, suggesting a link to tumor microenvironment biology.
Researchers analyzed tumor microenvironment of 26 patients with metastatic melanoma to identify patient response in advance of therapy. They found that specific immune cells, such as DC3s, are associated with improved overall survival and active T cell immune response.
Researchers have discovered that natural killer cells and interferon gamma play a crucial role in preventing cancer metastases. Targeted therapies, such as immunotherapy and interferon gamma therapy, show promise in maintaining dormant cancer cells in a state of hibernation.
Researchers have discovered a potential way to prevent Ewing sarcoma tumours from spreading by understanding how they develop a protective shield against the harsh environment of the bloodstream. This breakthrough may lead to the development of a clinical-grade immunotherapeutic treatment for Ewing sarcoma.
Researchers identify immunosuppressive cells as key link between obesity and cancer risk, progression, and metastasis. Altered metabolic factors in obesity activate these cells, leading to poor survival and resistance to immunotherapy in cancer patients.
Researchers discovered a two-stage process leading to aggressive pancreatic cancer, where protein loss allows for tumor transformation and immune evasion. The study suggests reinstating the classical subtype could reduce metastasis.
A new study reveals that small uveal melanomas have molecular genetic alterations, making them highly metastatic tumours. Prompt treatment can significantly increase the chances of cure for these patients.
Breast cancer researchers followed the progression of cancer in an animal model and found a path that transforms slow-growing ER+/HER2+ cancer into fast-growing ER-/HER2+ cancer. The study suggests different treatments may be needed for each subtype, depending on the path the cells follow.
A multidisciplinary study has found that cells at the centre of kidney tumours have a higher potential to spread to secondary sites around the body. By contrast, cells at the tumour edge had lower rates of metastasis and growth.
A new four-drug combination treatment has shown promise in preventing cancer metastasis without triggering drug resistance. The treatment targets multiple pathways to suppress cancer cell spread and may help identify patients who would benefit from such therapy.
A new approach uses T cell engineering to deliver the gene coding for IL-24, which targets cancer cells regardless of their expression of target molecules. This method blocks tumor growth, starves tumors of nutrients, and generates memory T cells that can theoretically kill tumors if they recur.
A recent study suggests that cancer prevalence in medieval Britain may be around 9-14%, significantly higher than the previous estimate of less than 1%. The research used x-rays and CT scans to analyze skeletal remains from six medieval cemeteries, revealing signs of malignancy in five individuals.